The UK healthcare community is abuzz with the arrival of Retatrutide, a novel dual GIP and GLP-1 agonist from Novo Nordisk. Initial patient data suggests this drug offers remarkable progress in weight reduction, https://andrewsiih925233.blog5.net/98786443/retatrutide-uk-an-emerging-hope-for-weight-loss